Cancer cells reprogram their metabolism using different strategies to meet energy and anabolic demands to maintain growth and survival. Understanding the molecular and genetic determinants of these metabolic programs is critical to successfully exploit them for therapy. Here, we report that the oncogenic melanocyte lineage-specification transcription factor MITF drives PGC1a (PPARGC1A) overexpression in a subset of human melanomas and derived cell lines. Functionally, PGC1a positive melanoma cells exhibit increased mitochondrial energy metabolism and reactive oxygen species (ROS) detoxification capacities that enable survival under oxidative stress conditions. Conversely, PGC1a negative melanoma cells are more glycolytic and sensitive to ROS-inducing drugs. These results demonstrate that differences in PGC1a levels in melanoma tumors have a profound impact in their metabolism, biology, and drug sensitivity.
INTRODUCTION
Tumors reprogram their metabolism to meet increased energetic and anabolic demands. A frequent metabolic adaptation that cancer cells acquire is an increase in glucose uptake and aerobic glycolysis together with decrease in oxidative metabolism. It is clear, however, that there is not one single tumor-specific metabolic state, and tumors can utilize a variety of different metabolic strategies that have only now begun to be elucidated. For example, tumor cells are able to generate ATP through mitochondrial oxidation of fatty acids and amino acids, such as glutamine when glucose becomes limiting (Zaugg et al., 2011; Choo et al., 2010; Gao et al., 2009; Wise et al., 2008 ).
An increase in reactive oxygen species (ROS), due to an enhanced and unbalanced metabolic activity (Hanahan and Weinberg, 2011 ) is a common stressor to which tumors must adapt. This increased generation of ROS can play a dual role in the cancer phenotype. On one hand, it can play a tumorigenic role by stimulating cell proliferation and promoting genomic instability (Weinberg and Chandel, 2009 ). On the other hand, above a certain threshold, ROS can be toxic and induce cellular damage, leading to cell death (Trachootham et al., 2009; Diehn et al., 2009) . Cancer cells develop adaptive responses against oxidative stress, often by upregulating their antioxidant-scavenging capacity. One clear example is the constitutive activation of the Keap1-Nrf2 pathway in squamous cell carcinomas, either by activating mutations in Nrf2 or through inactivating mutations in KEAP1 (an Nrf2 cytoplasmic repressor) (Padmanabhan et al., 2006; Singh et al., 2006; Shibata et al., 2008; Ohta et al., 2008) . Whereas some of these components of the oxidative stress response have been identified in cancer cells, it is likely that key regulators in this response that contribute to tumorigenesis are still missing.
PPARGC1A, named hereafter PGC1a, is part of a small family of transcriptional coactivators, including PGC1b and PRC, that promote mitochondrial biogenesis and respiration Scarpulla, 2011) . PGC1a is the best studied, particularly in brown fat, skeletal and cardiac muscle, liver, and fat tissues, where it is a key regulator of mitochondrial mass, thermogenic programs, and adaptation to fasting conditions (Kelly and Scarpulla, 2004) . PGC1a can also potently reduce generation of mitochondrial-driven ROS (St-Pierre et al., 2006) . PGC1a is typically expressed at low levels under normal conditions and is strongly induced and activated in response to increased metabolic and energetic demands in highly metabolic tissues. For example, exercise increases PGC1a levels in skeletal muscle, where it induces mitochondrial biogenesis and oxidative capacity (Handschin et al., 2007) . Cold exposure rapidly increases PGC1a levels in brown/beige adipose tissue to program a thermogenic response based on mitochondrial function (Puigserver et al., 1998) . In liver, fasting increases PGC1a to induce fatty acid oxidation, hepatic glucose production, and ketogenesis (Rhee et al., 2003) . In many of these cell types, the cyclic AMP (cAMP) pathway plays a central role through the activation of a cAMP response element binding protein (CREB) response element at the PGC1a promoter (Herzig et al., 2001) . Other signals contribute to increases in PGC1a gene expression, such as calcium signaling and MEF2 transcriptional activity in skeletal muscle (Lin et al., 2002) . It is unknown, however, whether and how oncogenic signals impact PGC1a expression and what are the metabolic and growth consequences this might cause to the tumor phenotype.
RESULTS

A Subset of Human Melanoma Tumors Expresses High Levels of PGC1a and Mitochondrial Genes of Oxidative Metabolism
Given the central role of PGC1a in oxidative metabolism and ROS detoxification in a variety of tissues Kelly and Scarpulla, 2004; Fernandez-Marcos and Auwerx, 2011; St-Pierre et al., 2006) , we hypothesized that PGC1a could be aberrantly activated in some tumors, thereby conferring them an adaptive advantage. Since PGC1a is strongly regulated at the messenger RNA (mRNA) level, publicly available gene expression databases were surveyed. In several data sets, a subset of melanoma tumors and melanoma-derived cell lines expressed very high relative levels of PGC1a mRNA. Figures 1A and S1A (available online) show the relative PGC1a mRNA levels from 56 melanoma tumors (GSE7553) (Riker et al., 2008) and 82 short-term melanoma cultures (Lin et al., 2008) . Levels of 10.7% for Riker melanoma data set and 8.4% for short-term melanoma cultures showed PGC1a expression levels that are at least one standard deviation above the average. To assess if the high PGC1a levels in these melanoma tumors were associated with its known metabolic gene expression program, we used Gene Set Enrichment Analysis (GSEA) to find gene expression signatures that correlated with PGC1a expression. Consistent with previous and established PGC1a targets in skeletal muscle cells (Mootha et al., 2003) , gene expression sets of mitochondrial genes, energy metabolism, and estrogen-related receptor alpha target genes were all significantly correlated with PGC1a expression in both melanoma tumors and short-term melanoma cultures ( Table 1; Table S1 ). Using an additional data set of metastatic melanoma tumors with clinical outcome data (Bogunovic et al., 2009) , we found that tumors expressing high PGC1a levels were associated with lower survival (long-rank p value 0.0230) compared to low PGC1a-expressing tumors ( Figure 1B) . The high and low expressing tumors were defined by selecting the top and bottom 25% PGC1a expressing tumors. Other clinical parameters were not affected ( Figure S1B ). The overexpression results were validated using patient-derived long-term melanoma cell lines. Remarkably, all melanoma cell lines tested fell into two categories with very high levels (PGC1a positive) or undetectable or very low levels (PGC1a negative) of PGC1a mRNA ( Figure 1C ) and protein ( Figure 1D ). PGC1a-positive cell lines had elevated levels of mitochondrial respiratory chain proteins from all different complexes tested ( Figure 1D ). These results suggest that PGC1a induces a mitochondrial metabolism gene expression program in these tumors and tumorderived cell lines.
To confirm that PGC1a was driving the mitochondrial metabolism gene expression signature, we used lentiviral small hairpin RNA (shRNA) to reduce its expression in a PGC1a-positive melanoma cell line (A375P) and performed gene-expression microarray followed by GSEA analysis. Similar gene expression sets of mitochondrial energy metabolism as the ones found in melanoma tumors and short-term melanoma cultures were enriched in control versus PGC1a knockdown cell lines ( Figure 1E ; Table  S2 ). Some of the targets were confirmed using quantitative PCR (qPCR) in A375P and two other PGC1a-positive melanoma cell lines (MeWo and G361) ( Figure 1F ). As expected, downregulation of mitochondrial genes in PGC1a-depleted A375P cells translated into decreases of protein levels. Several components of the oxidative phosphorylation complex were substantially decreased in PGC1a knockdown cells, particularly proteins that are part of Complex I and Complex IV ( Figure 1G ). PGC1a expression was also sufficient to induce this mitochondrial program. Modest ectopic expression of PGC1a in a PGC1a-negative cell line (A375, a metastatic clone derived from A375P) increased mitochondrial gene targets and protein levels (Figures S1C and S1D). We then compared the levels of PGC1a between nontransformed melanocytes and melanoma cells. The relative levels of PGC1a mRNA expression were measured in cultured immortal primary melanocytes and in a PGC1a-positive and negative melanoma cell lines. PGC1a mRNA expression levels in primary melanocytes were higher than PGC1a-negative melanoma cells but dramatically lower than PGC1a-positive melanoma cells ( Figure S1E ). Together, these results indicate that PGC1a is overexpressed in a subset of melanoma tumors and drives a mitochondrial gene expression program.
Interestingly, the overexpression of PGC1a and correlation with oxidative metabolism is not only present in melanomas.
We found that levels of PGC1a expression in lung adenocarcinoma cell lines also correlate with an oxidative metabolism signature ( Figure S1 ; Table S3 ).
MITF Expression in Human Melanoma Cells Drives High Levels of PGC1a Gene Expression
In order to identify the key factors responsible for the high levels of PGC1a expression in melanoma, we used publicly available data on gene expression, copy number, and mutations from the Cancer Cell Line Encyclopedia (CCLE) database (http:// www.broadinstitute.org/ccle) (Barretina et al., 2012) . We found no correlation between PGC1a copy number levels and gene expression. Only one melanoma cell line (SK-MEL1)-out of 60 melanoma cell lines with copy number data available at the time ( Figure S2A , data from the CCLE database)-was found to have PGC1a amplification, suggesting that amplification is not a common mechanism to increase PGC1a expression levels. Since p53 has been shown to negatively regulate PGC1a levels (Sahin et al., 2011; Sen et al., 2011) , we searched if there was an association between p53 mutation status and PGC1a expression, but no correlation was found in 60 cell lines with expression and mutation status data. Similarly, there was no correlation with BRAF mutations status ( Figure S2B ). The Riker melanoma data set was classified by their PGC1a expression levels to identify genes that were upregulated in high PGC1a versus low PGC1a-expressing tumors (Figure 2A ). Intriguingly, among the top classifying genes identified was microphthalmia-associated transcription factor (MITF), a melanocyte-lineage transcription factor and bona fide melanoma oncogene (Garraway et al., 2005; Yokoyama et al., 2011; Bertolotto et al., 2011) . Similar results were obtained comparing high-versus low-expressing PGC1a melanoma cell lines. Furthermore, the levels of several MITF downstream target genes, such as SLC45A2, CDK2, PMEL, TYR, TYRP1, MLANA, and DCT, were also differentially expressed ( Figure 2B , data from the CCLE database). Hence, within both melanoma specimens and melanoma cell lines, the (B) Kaplan-Meier survival curves for metastatic melanoma tumors with high and low PGC1a expression from data set GSE19232 (Bogunovic et al., 2009 Figure S1 and Tables S1-S3. expression levels of PGC1a correlated with MITF levels, indicating that they may be affecting each other in an epistatic manner. To forward this notion, we analyzed mRNA and protein levels of MITF in five PGC1a-positive and five PGC1a-negative cell lines. We found that both the mRNA and protein levels were higher in PGC1a-positive cell lines ( Figure 2C ). Interestingly, one of the outlier cell lines (SK-MEL-28) that expresses high levels of MITF but is PGC1a-negative expresses high levels of PGC1b.
Based on these data, we investigated if MITF was a causal driver for the high levels of PGC1a gene expression. Hence, we used lentiviral shRNA to reduce endogenous MITF levels in three PGC1a-positive melanoma cell lines (A375P, G361, and SK-MEL5) and found that it strongly downregulated PGC1a both at the mRNA and protein levels (Figures 2D and 2E) . Notably, PGC1a expression levels were suppressed even further than the known MITF target TYR. Moreover, PGC1a protein levels were almost undetectable after MITF knockdown. As expected, MITF knockdown-induced PGC1a downregulation resulted in decrease of PGC1a targets, including mitochondrial genes ( Figure S2C ). These results indicate that MITF is necessary to maintain high levels of PGC1a expression in PGC1a-positive melanoma cell lines.
Next we investigated whether MITF was sufficient to induce PGC1a expression in melanoma cell lines. Hence, ectopic expression of MITF using retroviral transduction in A375, a PGC1a-negative cell line, caused induction of PGC1a mRNA levels, including PGC1a targets, comparable to the known MITF target genes, TYR and DCT ( Figure 2F ). Because MITF is a transcription factor, it could directly bind the upstream regulatory promoter of PGC1a, as this region contains several E-boxes sequences ( Figure S2D ). Transfection of HEK293T cells with MITF induced a 2Kb PGC1a promoter-driving luciferase that was dependent on both E-boxes ( Figure 2Ga ). Conversely, MITF knockdown experiments in A375P cells reduced the activity of this promoter ( Figure 2Gb ). In addition, chromatin immunoprecipitation (ChiP) assays showed that endogenous MITF is bound to the PGC1a promoter ( Figure 2H ), consistent with previously reported ChiP sequencing data set ; Figure S2E ).
Gene expression profiling analysis of melanoma tumors has previously identified two expression signatures associated with proliferative or invasive phenotype. MITF expression was higher in melanoma samples with the proliferative signature and lower in samples with an invasive signature (Hoek et al., 2008) . Consistently, we found that melanoma tumors with high PGC1a levels also correlated with the proliferative signature ( Figure S2F ).
Collectively, these results indicate that MITF is necessary and contributes to the high levels of PGC1a expression found in a subset of human melanoma cells.
PGC1a Defines the Metabolic State of Melanoma Cells
To test whether PGC1a expression levels drive the metabolic program of melanoma cells, we compared key cellular metabolic and bioenergetic parameters between PGC1a-positive and negative melanoma cells. PGC1a-positive cells exhibited substantial increased basal and maximal oxygen consumption rates ( Figure 3A) . Additionally, the respiration reserve capacity, calculated by subtracting the basal to the maximal respiration capacity, was significantly higher in PGC1a-expressing melanoma cells. Glucose uptake was slightly decreased in PGC1a-positive cells that paralleled diminished levels of secreted lactate compared to PGC1a-negative cells ( Figure 3B ). Consistent with glycolytic metabolism generating lower ATP levels compared to oxidative metabolism, intracellular ATP levels of PGC1a-negative melanoma cell lines were reduced ( Figure 3B ). These differences in metabolic parameters were caused by PGC1a expression. Depletion of PGC1a levels in A375P largely recapitulated the metabolic and bioenergetic patterns of PGC1a-negative cells, e.g., decreased in basal, maximal, and reserved oxygen consumption rate (OCR) and intracellular ATP levels, decreased glucose uptake, and increased lactate production ( Figures 3C and 3D ). Metabolomic analysis showed that shRNA PGC1a cells had increased glycolytic but decreased tricarboxylic acid (TCA) intermediates ( Figure S3 ). In addition, a modest increase in PGC1a levels through forced expression ( Figure S1C ) in a PGC1a-negative cell line resulted in a reversal of these metabolic parameters ( Figure 3E ). In summary, these results indicate that cells with undetectable levels of PGC1a have lower rates of mitochondrial oxidative metabolism but elevated rates of glycolysis and lactate production consistent with a more pronounced glycolytic ''Warburg'' state. In contrast, PGC1a-positive cells have the reversed metabolic phenotype, leading to an elevated cellular energetic state.
PGC1a-Positive Melanoma Cells Are Dependent on PGC1a for Survival and Tumor Progression
Given the central role of PGC1a in the metabolic and energetic state of a subset of melanoma cells with high expression levels, we investigated whether these cells may have become dependent on PGC1a for survival. Thus, we suppressed the expression of PGC1a in five positive cell lines and measured its effect on cell viability. Figure 4A shows that knockdown of PGC1a significantly decreased cell number. As expected, knockdown of PGC1a had no significant effect on PGC1a-negative cells. As an additional control, we tested the effect of RPS6 knockdown in a PGC1a-positive and negative cell line and observed a similar effect of decreased cell number in both PGC1a-positive and negative cell lines ( Figure S4A ). Overexpression of PGC1a, similar to Gene expression of 56 melanoma tumors extracted from the GSEA7553 data set (Riker et al., 2008) was ranked for positive correlation with PGC1a expression and analyzed with the GSEA algorithm using the reactome gene sets; the significant (q < 0.25) gene sets ranked by normalized enrichment score are shown. NES, normalized enrichment score.
MITF, was not sufficient to induce proliferation in PGC1a-negative melanoma cells ( Figures S4B-S4D ) underscoring the context dependency of the effects. We next investigated the mechanism responsible for the reduced cell number after PGC1a knockdown. PGC1a knockdown resulted in a more than 3-fold induction in the percentage of apoptotic cells in two PGC1a-positive cell lines (A375P and MeWo) but not in a negative cell line (A375) ( Figure 4B ). This apoptosis was mediated through the intrinsic pathway, as caspases 9 and 3 but not 8 were activated in PGC1a-depleted cells. Other apoptotic markers, including cleavage of poly (ADP-ribose) polymerase (PARP), was also induced in PGC1a knockdown cells ( Figure 4C ). The apoptotic effect was largely reversed by overexpression of PGC1a, indicating that it is a result of PGC1a depletion ( Figure 4D ). To further support the involvement of caspases, the inhibitor Q-VD-OPH significantly reduced the number of cells entering apoptosis ( Figure 4E ). These results indicate that suppression of PGC1a activates the intrinsic mitochondrial apoptotic pathway and strongly suggest that PGC1a-positive melanoma cells have become dependent on PGC1a for survival.
PGC1a Suppression Results in a Reduction of ROS Detoxification Genes and Increase in ROS Levels Leading to Apoptosis
The fact that the intrinsic apoptotic pathway was activated in PGC1a-depleted cells suggested that the mitochondria was involved in the induction of apoptosis. One of the mechanisms by which mitochondrial failure causes apoptosis is through the loss of membrane potential and generation of ROS (Tait and Green, 2010) . Consistent with induction of this process, knockdown of PGC1a in A375P cells showed a strong decrease in mitochondrial membrane potential as measured using J-aggregation fluorescent assay ( Figure 5A ). Intracellular concentrations of ROS were significantly increased in PGC1a-depleted cells ( Figure 5B), and this was associated with a decrease in glutathione (GSH), cystathionine, and 5-adenosylhomocysteine levels ( Figure 5C ). Importantly, elevated ROS levels were necessary to mediate apoptosis in PGC1a knockdown cells, because two different antioxidants, N-acetyl-L-cysteine (NAC) and Trolox, largely suppressed caspase and PARP cleavages and the number of apoptotic cells ( Figure 5D ).
To determine whether ROS detoxification genes decrease in PGC1a-depleted cells and might contribute to apoptosis, we analyze the microarray data described in Figure 1 . Consistent with previous data in non-transformed cells (St-Pierre et al., 2006) , a set of genes involved in the ROS detoxification, including different glutathione synthase enzymes, thioredoxins, glutaredoxin, peroxiredoxins, and SOD2, were decreased in PGC1a knockdown cells. These results were confirmed using qPCR of several of these genes ( Figure 5E ). SOD2 protein levels were substantially decreased in PGC1a-depleted melanoma cells ( Figure 5F ). Moreover, ectopic expression of PGC1a in A375 increased ROS detoxification genes ( Figure 5G ). These data supports a key role for PGC1a in activating the ROS detoxification gene program to maintain melanoma cell survival.
As we have showed that PGC1a is a target of MITF, we next investigated the role of PGC1a downstream of MITF in promoting survival and proliferation. Overexpression of PGC1a could partially overcome the effects of knockdown MITF on DNA damage and increase of p27 levels ( Figure S5A ). In addition, treatment of MITF-depleted cells with the antioxidant NAC partially blocked the apoptotic effects ( Figure S5B ). Together, these results suggest that downregulation of PGC1a contributes to the phenotypic effects of MITF knockdown in PGC1a-expressing cells.
Depletion of Several PGC1a Respiratory Chain Targets Mimic the Metabolic and ROS-Dependent Apoptotic Effects of PGC1a Suppression
The reduction in ROS detoxification genes and GSH levels could be one of the mechanisms by which depletion of PGC1a in melanoma cells induces intracellular ROS levels. However, defects in mitochondrial bioenergetic function are also known to generate toxic ROS levels. Thus, to understand how PGC1a deficiency caused ROS-mediated apoptosis, we tested whether knockdown of different proteins of the mitochondrial respiratory complexes, which are PGC1a targets, produced similar metabolic and apoptotic defects as PGC1a depletion. Therefore, Ndufs3, Cox5a, and ATP5b were efficiently knocked down in A375P melanoma cells ( Figure 6A ). Individual depletion of these three mitochondrial proteins caused a similar metabolic phenotype as PGC1a knockdown cells, leading to decreases in oxygen consumption and increases in glucose uptake and lactate secretion ( Figures 6B and 6C) . Consistent with an increase in intracellular ROS levels in these cells, GSH levels were also decreased ( Figure 6D ). Moreover, increased ROS concentrations caused by depletion of these mitochondrial proteins lead to increased cleavage of proapoptotic proteins ( Figures 6E and  6F) . To support the role of ROS mediating cell death, treatment with antioxidants NAC and Trolox largely prevented PARP cleavage ( Figure 6G ). Together, these results suggest that PGC1a-positive melanoma cells are highly sensitive to the induction of ROS due, at least in part, to the disruption of the mitochondria respiratory complex.
PGC1a Protects against ROS-Induced Apoptosis in Human Melanoma Cells and Tumors
The increased ROS levels in cancer cells makes them more dependent in their antioxidant capacity for cell survival, a principle that is exploited by anticancer drugs, such as piperlongumine or phenethyl isothiocyanate (PEITC). In fact, transformed cells have been shown to be exquisitely more sensitive to ROS-inducing drugs than nontransformed cells (Trachootham et al., 2006; Raj et al., 2011) . Based on the results presented above that PGC1a controls the antioxidant capacity affecting cell survival, we investigated if PGC1a, by reducing ROS levels and enhancing the antioxidant capacity, could influence the sensitivity to ROS-inducing drugs in melanoma cells. Depletion of PGC1a in A375P cells enhanced their sensitivity to apoptosis induced by H 2 O 2 , PEITC, or piperlongumine, all of which are known to increase intracellular ROS concentrations (Trachootham et al., 2006; Raj et al., 2011) . These effects were not generalized to all drugs, as the B-Raf inhibitor PLX4032 had similar effects in PGC1a control or knockdown A375P cells ( Figures 7A and S6A) . Furthermore, similar effects on the sensitivity to these compounds were observed after knockdown of several mitochondrial proteins (Ndufs3, Cox5a, and ATP5b) PPARGC1A  ZNF749  DYNC1I1  C1ORF115  VEPH1  KRTAP19-3  QPCT  C9ORF93  SLC11A2  GHR  HOXA13  PPP1R1A  PRKD3  HPS4  PPM1H  TRIM63  RAB27A ( Figure 7A ). Consistent with these results, piperlongumine had a more potent effect, inducing apoptosis in PGC1a-negative cells ( Figures 7B and 7C) . Furthermore, ROS levels after piperlongumine treatment were higher in four out of the five PGC1a-negative compared to five PGC1a-positive cell lines tested ( Figures 7D and S6B ). To further support the role of 
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PGC1a-mediating resistance to ROS-induced apoptosis, ectopic expression of PGC1a in PGC1a-negative cell lines prevented piperlongumine-induced cleavage of caspase 9 and PARP ( Figure 7E ). Finally, to evaluate the impact of PGC1a depletion on tumor growth, subcutaneous injections of control and PGC1a-depleted A375P cells were performed in nude mice and the size of the resulting tumors was measured. As shown in Figure 8A , there was a significant reduction in tumor size in PGC1a-depleted cells, suggesting that PGC1a is important for tumor progression. Importantly, piperlongumine treatment for 7 days had a greater reduction of tumor volume of xenografts derived from PGC1a knockdown cells compared to control xenografts. The magnitude of these effects correlated with induction of apoptotic markers in these tumors ( Figure 8B ). The growth of these tumors did not affect body weight ( Figure 8C ). Collectively, these data suggest that PGC1a expression confers resistance to drugs that induce intracellular ROS levels in melanoma cells and tumors.
DISCUSSION
Cancer cells reprogram their metabolism to meet anabolic and energetic demands necessary for growth and survival. It is becoming clear, however, that tumor cells do not employ a single strategy to accomplish this, as cancers can choose from a variety of metabolic programs to meet their demands. Here, we provide a clear example of this metabolic reprogramming heterogeneity by showing that cells derived from the one tumor type can have profound differences in their metabolic state. In melanomas, expression levels of PGC1a metabolically define two types of tumors with different bioenergetic and ROS detoxification capacities, thereby affecting the ability to survive under oxidative stress. It is conceivable that, in certain low nutrient conditions, elevated mitochondrial capacity might be more efficient to generate ATP necessary for survival without compromising anaplerotic reactions to support cell growth.
Our findings show that a subset of melanoma cells acquire high levels of PGC1a that depend on an increased activity of the melanoma oncogene MITF. This would confer a selective advantage to melanocytic tumor cells by providing a strong protection against oxidative damage. A large subset of melanoma tumors has very low or undetectable levels of PGC1a that, to a large extent, overlaps with low levels of MITF. These less differentiated tumors use a different metabolic strategy of increased glycolysis for growth and survival. It is also possible that melanoma tumors transit through different states during tumor progression with high or low expression levels of PGC1a. In fact, we provide here an example of this possibility: the PGC1a-negative melanoma cell line A375 was derived from a metastatic tumor produced by the PGC1a-positive parental cell line A375P (Clark et al., 2000) . It is likely that A375 cells lost their melanocytic differentiation state, since they express very low levels of MITF and differentiation markers. Concomitant to this loss of differentiation, they became MITF and PGC1a independent for tumor progression. Thus, similar to MITF, PGC1a effects on melanomagenesis may be context dependent. PGC1a controls MITF gene expression. contributing to the maintenance of survival in melanomas. Interestingly, peroxisome proliferator-activated receptor g, a transcription factor known to bind PGC1a (Puigserver et al., 1998) , regulates MITF (Grabacka et al., 2008) , suggesting that it might be involved in this process.
These results provide the basis for some potential anticancer therapeutic strategies targeting cellular metabolism. PGC1a-positive cells depend on PGC1a for survival, suggesting that PGC1a itself or one of its target genes could be a therapeutic target. In this regard, although small molecules targeting PGC1a do not currently exist, inhibitors of estrogen-related receptors (ERRs), key PGC1 transcription factor partners (Mootha et al., 2004; Chang et al., 2011; Schreiber et al., 2004; Eichner and Giguè re, 2011; Wende et al., 2005) , could potentially be used to inhibit PGC1a function. Because several transcription factors, including nuclear respiratory factors, ERRs, and YY1 (Scarpulla, 2011; Knutti and Kralli, 2001; Cunningham et al., 2007) , control PGC1a function, future studies will focus to assess which transcription factor(s) partners with PGC1a to control mitochondrial function and ROS detoxification genes in melanomas. Our data also show that PGC1a-positive cells are more sensitive to disruption of mitochondrial respiration, suggesting that specific inhibition of respiratory chain complexes could be another vulnerability that could be exploited in this tumor subtype. Importantly, melanoma cells can adapt their metabolism and become PGC1a independent, underscoring metabolic flexibility as a potential hurdle on developing drugs against metabolic targets. Conversely, PGC1a-negative melanoma cells have reduced bioenergetic capacity together with lower levels of antioxidant enzymes. As a result, these tumor cells are more sensitive and vulnerable to toxic oxidative stress. This metabolic vulnerability provides a therapeutic strategy to treat this subtype of melanoma tumors (Figure 7) . In fact, here we find that ROS-inducing drugs, such as piperlongumine or PEITC, that have been shown to preferentially kill transformed over normal cells (Raj et al., 2011; Trachootham et al., 2006) showed increased potency in PGC1a-negative melanoma cells.
In summary, our work has revealed that melanoma tumors present heterogeneous metabolic and energetic states defined by levels of PGC1a expression. These studies illustrate how reprogramming metabolism and energy in tumor cells is genetic dependent and how this information might be used to develop cancer therapy targeting regulatory metabolic networks.
EXPERIMENTAL PROCEDURES
Cell Culture and Virus Infection Melanoma cell lines were cultured in high glucose Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Immortalized primary melanocytes transduced with pBABE-hygro-hTERT, pLNCX2-CDK4(R24C), and pBABE-puro-p53DD were generated as described (Garraway et al., 2005) . Lentiviruses were produced by transfecting HEK293T cells with pLKO and packaging vectors, as previously described (Moffat et al., 2006) using PolyFect (QIAGEN). Retroviral particles were produced by transfecting HEK293T cells with the pBabe or pWZL vectors and packaging vector (pCL-Ampho) using PolyFect (QIAGEN). GFP control and Flag-HA-PGC1a adenovirus have been previously described (Lerin et al., 2006) .
Animal Studies
All animal studies were performed with an approved protocol from the Beth Israel Deaconess Medical Center Institutional Animal Care and Use Committee 
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PGC1a Programs Oxidative Metabolism in Melanoma (Protocol number 105-2011) . For xenograft studies, 1 3 10 6 A375P cells stably expressing scrambled shRNA control or PGC1a shRNA were injected subcutaneously into the flank of nude mice (Taconic) in 100 ml of media. After cell injection, mice were incubated for 15 days to allow tumor growth, and then mice were treated with DMSO or piperlongumine (1.5 mg/kg, intraperitoneally [i.p.]) once a day for 6 days. Tumor volumes were measured with a caliper and calculated using the equation volume = ab 2 /2, where ''a'' is the maximal width and ''b'' is maximal orthogonal width.
Arrays and Gene Set Enrichment Analysis
To generate gene-expression arrays, A375P cells were infected with a control shRNA (small hairpin GFP or scrambled short hairpin RNA) or a PGC1a shRNA (E) Analysis of apoptosis using cleavage of apoptotic markers in PGC1a-negative melanoma cell lines ectopically expressing PGC1a and treated with piperlongumine. See also Figure S6 .
(described in Supplemental Experimental Procedures) in duplicate and selected with puromycin for 48 hr. Four days after selection, RNA was extracted and gene expression arrays were performed using Human Genome U133A 2.0 arrays. To create a gene expression file, CEL files were used as input for the GenePattern (http://www.genepattern.broadinstitute.org) module Expression File Creator using robust multiarray average (RMA) and quantile normalization. The gct file created was used as input for the GSEA analysis. For the melanoma tumors gene expression analysis, the normalized data set GSE7553 was imported from GEO using the software Gene-e (http://www. broadinstitute.org/software/gene-e). The melanoma samples from the data set were selected to create a gct file. This gct file was used as input for the GSEA algorithm.
To find differentially expressed genes, the probes' values were collapsed using maximum average probe and log2 transformed. The signal to noise marker selection tool from Gene-e was used to find genes differentially expressed between the top and the bottom 25% PGC1a-expressing melanoma tumors with 10,000 permutations. The cutoff to select the gene list was fold change >2, false discovery rate (FDR) q < 0.25. For the melanoma cell lines gene expression analysis, the gene-centric RMA-normalized CCLE expression data set was used (http://www.broadinstitute.org/ccle).
The GSEA software v2.0 (http://www.broadinstitute.org/gsea; Subramanian et al., 2005) was used to perform the GSEA analysis. In all the analysis, the Reactome gene sets were used and the number of permutations was changed to 5,000. For the GSEA7553 slice data set, the values of the 219195_at probe (corresponding to PPARGC1A) were used as phenotype and the default parameters were used with the exception that Pearson correlation was computed to rank the genes. For the analysis of the A375P data set, the default parameters were used but the permutation type was changed to gene set.
Oxygen Consumption
The oxygen consumption rate was measured using an optical fluorescent oxygen sensor in a Seahorse Bioscience XF24 Extracellular Flux Analyzer. Briefly, cells were seeded in quadruplicate at equal densities (25,000 cells per well) into XF24 tissue culture plates. Cell media was changed 12 hr after cell seeding into unbuffered Dulbecco's modified Eagle's medium (DMEM) (8.3 g/l DMEM [Sigma], 200 mM GlutaMax-1 [Invitrogen], 25 mM D-glucose [Sigma], 63.3 mM NaCl [Sigma] , and phenol red [Sigma] , adjusted pH to 7.4 with NaOH), according to the manufacturer's protocol. Oxygen consumption was measured under basal conditions and mitochondrial uncoupler trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP) (2 mM). Oxygen consumption values were normalized to cell number.
Intracellular ROS and Cellular GSH Levels
To measure intracellular ROS levels, 2 mM dichlorofluorescein diacetate (DCF-DA) (Invitrogen) was used as a fluorescent dye. An equal number of cells were seeded in six well plates, after 72 hr cells were trypsinized, washed once with PBS, and stained with DCF-DA in Hank's balanced salt solution for 30 min at 37 C. Samples were then immediately analyzed by flow cytometry.
A glutathione colorimetric detection kit (BioVision Research Products) was used to measure total cellular glutathione according to the manufacturer's instructions. 
